INVA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IN

Mkt Cap

$1.50B

Volume

422.25K

Next Earnings

November 4th

Loading chart

IN

INVAInnoviva, Inc. Common Stock

INVA

Pay with—

Available Balance0.00

IN

Mkt Cap

$1.51B

Volume

422.25K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

INVA vs. MRK: Which Stock Is the Better Value Option?In a comparison of two large cap pharmaceutical stocks, Innoviva (INVA) emerges as the superior value option compared to Merck (MRK). INVA holds a Zacks Rank of #2 (Buy) versus MRK's #3 (Hold), and demonstrates significantly better valuation metrics including a forward P/E of 9.12 versus MRK's 53.42, a PEG ratio of 3.04 versus 6.42, and a P/B ratio of 1.24 versus 8.4. INVA received a Value grade of A while MRK received a C.Zacks Investment Research · Oct 8, 2026

5 Attractive Low Price-to-Sales Stocks With Promising Upside PotentialThe article identifies five stocks with low price-to-sales ratios and strong fundamentals as potential value investments: HF Sinclair, Innoviva, Par Pacific Holdings, Genworth Financial, and PBF Energy. All five companies meet screening criteria including low valuations relative to industry peers, solid financial metrics, and positive Zacks Rank ratings, suggesting they may offer attractive returns for value-focused investors.Zacks Investment Research · Oct 8, 2026

Should Value Investors Buy Innoviva (INVA) Stock?Zacks highlights Innoviva (INVA) as an attractive value stock with a Zacks Rank #2 (Buy) rating and an A grade for Value. The stock trades at a P/E ratio of 10.12 compared to its industry average of 17.64, and shows favorable valuations across multiple metrics including P/S ratio of 3.46 and P/CF ratio of 20.06, suggesting it is currently undervalued.Zacks Investment Research · Oct 8, 2026

3 Bargain-Cheap Small Caps Worth a Second LookThe article examines three small-cap stocks with low P/E ratios that may offer value opportunities. Innoviva Inc. (INVA) is a biotech company with a diversified business model including royalties and strategic investments, with analysts projecting a 50% upside despite a projected 2026 earnings decline. Wendy's (WEN) faces consumer headwinds but is controlling costs and offers an 8%+ dividend yield, potentially attractive if economic conditions improve. Nabors Industries (NBR) is a momentum play in oil and gas drilling services that has benefited from rising oil prices, though upside from current levels is limited.Investing.com · Apr 9, 2026

Tetracyclines Market is Poised to Garner Valuation of USD 5.63 Billion by 2035 | Astute AnalyticaThe global tetracyclines market is experiencing steady growth at a CAGR of 5.23%, driven by broad-spectrum efficacy, cost-effectiveness, and expanding applications in respiratory infections, dermatology, and sexual health. Doxycycline dominates with 46.1% market share, while oral formulations lead with 64.0% share. Key growth drivers include rising antibiotic demand in veterinary and aquaculture sectors, emerging clinical applications like Doxy-PEP, and robust supply chains from China and India.GlobeNewswire Inc. · Feb 10, 2026

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand OutTwo biotech companies are highlighted as standout investments for 2026. Axsome Therapeutics has strong late-stage pipeline developments with FDA acceptance of supplemental applications for AXS-05 in Alzheimer's agitation treatment and support for AXS-12 for narcolepsy, with 19 of 20 analysts rating it a Buy and targeting 8% upside. Innoviva received FDA approval for Nuzolvence, a first-in-class oral antibiotic for gonorrhea with significant market potential, and has shown strong financial performance with analyst consensus price target nearly double current trading levels.Investing.com · Jan 8, 2026

Innoviva (INVA) Q2 Sales Jump 64%Innoviva reported Q2 2025 earnings with $0.77 EPS and $100.3 million revenue, exceeding analyst expectations. Specialty therapeutics sales increased 54% year-over-year, driven by new product launches like GIAPREZA and ZEVTERA, while operating income declined due to increased R&D expenses.The Motley Fool · Aug 7, 2025

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United StatesBasilea Pharmaceutica Ltd has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc. for the commercialization of Basilea's hospital anti-MRSA antibiotic Zevtera® (ceftobiprole) in the United States.GlobeNewswire Inc. · Dec 16, 2024

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory DrugsCantor Fitzgerald has initiated coverage on Innoviva, Inc. (NASDAQ:INVA), citing the company’s unique business model centered around royalties and healthcare assets. The company receives royalties from GSK plc (NYSE:GSK) for popular asthma and COPD products, including Relvar/Breo and Anoro, with combined sales of over $2 billion in 2023. “We believe their manufacturing complexity provides further protection from potential competitors,” Cantor analyst writes. Cantor projects around $1.1 billion of 5-year projected royalty revenues from GSK and initiates Innoviva with an Overweight rating. The analyst says Breo and Anoro have exceeded expectations, even during challenging times such as the COVID-19 ...Full story available on Benzinga.comBenzinga · Jun 18, 2024

10 stocks you can bet on being inflation-proofHigh-quality stocks can do well when prices are rising or falling. Here’s why.MarketWatch · Mar 2, 2024

to start trading

IN

INVAInnoviva, Inc. Common Stock

INVA

Pay with—

Available Balance0.00

Your PositionYou don't own any INVA yet.

Related Tickers

Earnings